Insider Selling: enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder Sells $717,810.00 in Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now owns 3,036,153 shares of the company’s stock, valued at approximately $45,542,295. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The stock was sold at an average price of $15.01, for a total value of $68,670.75.

enGene Stock Down 3.3 %

Shares of ENGN opened at $14.75 on Thursday. enGene Holdings Inc. has a 52-week low of $6.69 and a 52-week high of $43.00. The company has a 50-day moving average of $16.23.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Fcpm Iii Services B.V. purchased a new stake in shares of enGene during the 4th quarter worth approximately $80,097,000. Omega Fund Management LLC acquired a new position in enGene during the fourth quarter worth $10,441,000. BVF Inc. IL purchased a new stake in enGene during the fourth quarter worth $20,777,000. Finally, Vivo Capital LLC acquired a new stake in enGene in the fourth quarter valued at $6,264,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ENGN has been the topic of several recent research reports. Guggenheim began coverage on shares of enGene in a research note on Monday, April 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. SVB Leerink initiated coverage on shares of enGene in a research report on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price objective for the company. Wells Fargo & Company initiated coverage on enGene in a report on Monday. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, UBS Group assumed coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $34.40.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.